Skip to main content
SpringerLink
Log in
Book cover

Nephrologie pp 81–89Cite as

Nebenwirkungen der Therapie der renalen Anämie mit rekombinantem humanem Erythropoietin

  • Conference paper

Part of the book series: Innovative Aspekte der Klinischen Medizin ((KLIN MED,volume 1))

Zusammenfassung

Das von Genetics Institute (Cambridge, Massachusetts) und Boehringer Mannheim GmbH gemeinsam entwickelte humane Erythropoietin (rhEPO) wird seit März 1987 als Therapeutikum für die renale Anämie bei Hämodialysepatienten eingesetzt. Die ersten beiden durchgeführten klinischen Studien waren

  1. 1)

    eine multizentrische kontrollierte Studie zum Nachweis der Stimulierbarkeit der Erythropoese, zur Dosisfindung und zum Langzeiteinsatz des rhEPO und

  2. 2)

    eine monozentrische Studie, in der die Auswirkungen des rhEPO auf den Eiweiß- und Erythrozytenstoffwechsel untersucht werden sollten.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Böcker A, Reimers E, Nonnast-Daniel B et al. (1988) Effect of Erythropoietin treatment on 02 affinity and performance in patients with renal anemia. In: Koch KM, Kühn K, Nonnast-Daniel B, Scigalla P (eds) Treatment of renal anemia with recombinant erythropoietin = Contributions to nephrology, vol 66. Karger, Basel (Int Workshop treatment of renal anemia with recombinant Erythropoietin/Wolfenbüttel, pp 165–175)

    Google Scholar 

  2. Bommer J, Müller-Bühl E, Ritz E, Eifert J (1987) Recombinant human Erythropoietin in anaemic patients in haemodialysis. Lancet I: 392, No. 8529

    Article  Google Scholar 

  3. Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P (1988) Dose related effects of recombinant human Erythropoietin on erythropoiesis. In: Koch KM, Kühn K, Nonnast-Daniel B, Scigalla P (eds) Treatment of renal anemia with recombinant Erythropoietin = Contributions to nephrology, vol 66. Karger, Basel, pp 85–93

    Google Scholar 

  4. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant Erythropoietin in patients having haemodialysis. Br Med J [Clin Res] 295: 1017–1020, No 6605

    Article  CAS  Google Scholar 

  5. Eschbach JB, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human Erythropoietin results of a combined phase I und II clinical trial. N Engl J Med 316: 73–78, No. 2

    Article  PubMed  CAS  Google Scholar 

  6. Grützmacher P, Scheuermann E, Loew I et al. (1988) Correction of renal anaemia by recombinant human Erythropoietin: effects on myocardial function. In: Koch KM, Kühn K, Nonnast-Daniel B, Scigalla P (eds) Treatment of renal anemia with recombinant Erythropoietin = Contributions to nephrology, vol 66. Karger, Basel (Int Workshop treatment of renal anemia with recombinant Erythropoietin/Wolfenbüttel pp 176–184

    Google Scholar 

  7. Kühn K, Nonnast-Daniel B, Grützmacher P, Grüner J, Pfaeffl W, Baldamus CA, Scigalla P (1988) Analysis of initial resistance of erythropoiesis to treatment with recombinant human Erythropoietin. Results of a multicenter trial in patients with end-stage renal disease. In: Koch KM, Kühn K, Nonnast-Daniel B, Scigalla P (eds) Treatment of renal anemia with recombinant Erythropoietin = Contributions to nephrology, vol. 66. Karger, Basel (Int Workshop treatment of renal anemia with recombinant Erythropoietin/Wolfenbüttel pp 94–103)

    Google Scholar 

  8. Moia M, Vizzotto L, Cattaneo M, Mannuccio Mannucci P, Casati S, Ponticelli C (1987) Improvement in the haemostatic defect of uraemia after treatment with recombinant human Erythropoietin. Lancet II: 1227–1229, No. 8570

    Article  Google Scholar 

  9. Reimers E, Böcker A, Nonnast-Daniel B et al. (1988) Behandlung der renalen Anämie mit rekombinantem humanem Erythropoietin (rhEPO): Auswirkungen auf HB-02-Affinität und körperliche Leistungsfähigkeit. Klin Wochenschr 66: 189 (Abstract-No 413, Suppl 13 Tagg Dtsch Ges Inn Med 94./Wiesbaden/1988)

    Google Scholar 

  10. Schäfer RM, Kürner B, Zech M, Krahn R, Heidland A (1988) Therapie der renalen Anämie mit rekombinantem humanem Erythropoietin. Dtsch Med Wochenschr 113: 125–129, No. 4

    Article  Google Scholar 

  11. Valderrabano F (1988) Adverse effects of recombinant human Erythropoietin in the treatment of anaemia in chronic renal failure 25th EDTA-Congress, Madrid, Abstract p 216

    Google Scholar 

  12. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human Erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis Lancet II:1175–1177, No. 8517

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Produktentwicklung Therapeutika, Boehringer Mannheim GmbH, Germany

    P. Scigalla, D. Messinger, B. Ehmer, E. M. Woll & L. Wieczorek

Authors
  1. P. Scigalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Messinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Ehmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. M. Woll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Wieczorek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Med. Klinik I Nephrologische Abteilung, Klinikum Großhadern, Marchioninistraße 15, 8000, München 70, Deutschland

    Hans-Jürgen Gurland

  2. Abteilung Nephrologie, Zentrum für Innere Medizin und Dermatologie, Med. Hochschule Hannover, Konstanty-Gutschow-Str. 8, 3000, Hannover 61, Deutschland

    Karl Martin Koch

  3. Zentrum der Inneren Medizin, Klinik d. J.-W.-Goethe-Univ., Theodor-Stern-Kai 7, 6000, Frankfurt 70, Deutschland

    Wilhelm Schoeppe

  4. Produktentwicklung Therapeutica, Boehringer Mannheim GmbH, Sandhofer Straße 116, 6800, Mannheim 31, Deutschland

    Paul Scigalla

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag, Berlin-Heidelberg New York

About this paper

Cite this paper

Scigalla, P., Messinger, D., Ehmer, B., Woll, E.M., Wieczorek, L. (1989). Nebenwirkungen der Therapie der renalen Anämie mit rekombinantem humanem Erythropoietin. In: Gurland, HJ., Koch, K.M., Schoeppe, W., Scigalla, P. (eds) Nephrologie. Innovative Aspekte der Klinischen Medizin, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74961-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74961-2_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-51475-6

  • Online ISBN: 978-3-642-74961-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation